Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	113266
Country	China

Category	Oncology
Manuscript Type	Systematic Reviews
Article Title	Cost-effectiveness analysis of seven treatments vs sorafenib as first-line therapy for advanced hepatocellular carcinoma in China
Manuscript Source	Unsolicited Manuscript
All Author List	Zhi-Huan Lin, Yan He, Hai-Xia Xu and Liang Xiao
Funding Agency and Grant Number	Funding Agency Grant Number Natural Science Foundation of Shen Zhen City No. JCYJ20220530151002004
Corresponding Author	Hai-Xia Xu, MD, Department of Medical Oncology, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, No. 3002 Sungang West Road, Futian District, Shenzhen 518035, Guangdong Province, China. xhx198345@vip.163.com
Key Words	Hepatocellular carcinoma; Cost-effectiveness; Network meta-analysis; First-line treatment; China
Core Tip	The economic evaluation of various first-line treatment regimens for advanced hepatocellular carcinoma is crucial, yet such analyses remain scarce. This study conducted a network meta-analysis of 23 first-line regimens for advanced hepatocellular carcinoma and subsequently performed a cost-effectiveness analysis on seven highly efficacious regimens from the perspective of the Chinese healthcare system. The results indicated that lenvatinib combined with transarterial chemoembolization emerged as the most favorable first-line treatment under current economic conditions in China, achieving a 67.9% probability of being the most cost-effective option. This study contributes a novel perspective to inform clinical decision-making for healthcare professionals.
Citation	Lin ZH, He Y, Xu HX, Xiao L. Cost-effectiveness analysis of seven treatments vs sorafenib as first-line therapy for advanced hepatocellular carcinoma in China. World J Gastrointest Oncol 2026; In press

Received	2025-08-20 04:05
Peer-Review Started	2025-08-20 04:05
First Decision by Editorial Office Director	2025-10-10 03:13
Return for Revision	2025-10-10 03:13
Revised	2025-11-23 08:34
Publication Fee Transferred	2025-11-26 10:01
Second Decision by Editor	2026-01-13 02:34
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2026-01-14 06:41
Articles in Press	2026-01-14 06:41
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	1948-5204 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com